Mechanism & significance

The wrong metal can block the right nutrient

  1. Compete at the entry point

    PsaA normally captures manganese for S. pneumoniae. When extracellular zinc is sufficiently high relative to manganese, Zn(II) competes for the same binding site. [1]

  2. Trap the binding protein

    Zinc forms an unusually stable PsaA complex that releases its metal poorly. Manganese accumulation falls even though intracellular zinc changes little: the transport gateway becomes a bottleneck. [1]

  3. Lose oxidative defenses

    Manganese starvation slows growth and makes the pneumococcus more sensitive to oxidative stress and neutrophil killing. The consequence follows from depriving manganese-dependent defenses of their resource. [1]

Why this matters

Zinc toxicity can operate through another metal's shortage. This gives a testable prediction: susceptibility should track the zinc-to-manganese balance and PsaA function, rather than zinc concentration alone. [1]

What the experiments show

  • Competition at the gateway. In Streptococcus pneumoniae, zinc binding to PsaA impaired manganese acquisition and weakened oxidative-stress defenses. A harmful zinc exposure can therefore act through deprivation of another metal. [1]
  • Restriction can select competitors. In the inflamed mouse gut, high-affinity zinc acquisition supported Salmonella competition under calprotectin-mediated withholding. That advantage belongs to a particular acquisition system in a particular niche. [2]
  • Supply can alter community resistance. In a mouse C. difficile model, excess dietary zinc altered the microbiota and increased susceptibility in an antibiotic-dependent setting. The dietary salts were carbonate—not oxide—and the study did not test MS. [3]

The broader picture

Zinc can inhibit a bacterium by blocking its access to manganese. In Streptococcus pneumoniae, zinc occupies a metal-binding gateway and leaves the cell less able to resist oxidative attack. Elsewhere, high-affinity zinc uptake helps microbes compete under host zinc withholding. The local metal mixture and the acquisition machinery determine the outcome. [1][2]

Experiments worth knowing

Inflamed mouse intestine

Different competitors experience the same restriction differently

Study design. Host and microbial genetic comparisons, supported by culture studies.

What they found. The competitive defect associated with loss of ZnuA was relieved in calprotectin-deficient hosts. [2]

How to read it. This supports a host–microbial acquisition interaction; it is not a measurement of zinc competition in human MS.

Mouse C. difficile infection

Antibiotic context changes the dietary result

Study design. Dietary intervention with antibiotic and infection comparisons.

What they found. High dietary zinc worsened infection outcomes under the studied conditions; without antibiotics, the diets did not permit colonization. [3]

How to read it. The interaction matters. This is not a human oxide-versus-aspartate trial.

Community & host evidence

MS-associated communities have produced immune effects in cell and mouse experiments, but those experiments did not identify zinc handling as the causal function. Their findings cannot be joined to a zinc absorption trial as though the microbial mechanism had been measured. [4]

Exposure & chemical form

Formulation performance depends partly on dissolution conditions. A small gastric-pH study found the lowest plasma zinc response with oxide at higher pH. This was not an isotope absorption trial or a test of microbial exclusion. Ordinary oral oxide and zinc-oxide nanoparticle antimicrobial studies also describe different exposures. [5]

Follow the metal

A zinc result needs a compartment

Measurements that answer different questions
Pool or signalWhat the evidence measuresWhat it cannot identify alone
BloodOne MS cohort had lower average serum zinc than controls, generally within reference ranges; treatment was a relevant covariate.Whole-body depletion, intestinal microbial capture, or zinc inside a specific immune-cell population. [6]
Chronic MS lesionsElemental imaging found lower zinc in chronic white-matter lesions than in surrounding normal-appearing white matter, accompanying myelin loss.A labile intracellular pool; the iron-rich lesion-rim pattern should not be reassigned to zinc. [7]
Immune cellsA ZIP3 study linked cytosolic zinc regulation to pathogenic Th17-cell function in EAE.That a human dietary zinc form caused the cellular state or would correct it. [8]
CalprotectinAn inflammatory protein with metal-withholding activity.Zinc-binding occupancy, microbial zinc uptake, or the source of a patient’s low circulating zinc. [2]

Use “hypozincemia” for low circulating zinc. Describe low or excess tissue zinc with its anatomical and chemical context. Lower serum zinc and a zinc-dependent pathogenic cell process are not logically inconsistent; they concern different pools.

Follow the metal

Formulation evidence: compare like with like

What the zinc studies actually compared
Study and settingObserved resultBoundary of inference
Aspartate / gluconate / sulfate · 8 healthy adultsGreater estimated fractional absorption with aspartate in a crossover study with milk.Preliminary, indirect urinary isotope estimate; no oxide, microbes, or MS arm. [9]
Citrate / gluconate / oxide · 15 healthy adults, without foodOxide absorption was lower; a few participants absorbed little or none.Different conditions and isotope method; no aspartate arm. [10]
Oxide / aspartate and other forms · digestion and Caco-2 modelOxide was somewhat less available in the tested intestinal model.An in vitro comparison is not a human head-to-head trial. [11]

Higher host absorption does not establish intact-chelate transport, bacterial exclusion, or preferential delivery to the cells that need zinc. Less unabsorbed mass might alter microbial exposure, but the chemical availability and site of that residual zinc remain separate questions. The human studies above cannot prove that aspartate goes straight to the host while oxide feeds its microbiota.

Follow the metal

MS: separate the evidence before connecting it

Animal intervention

Aspartate has a genuine preclinical signal.

Oral zinc aspartate reduced clinical and histopathological EAE signs. [12]

What is still needed. Human MS efficacy, a direct oxide comparator, and microbial mediation.

Small human trial · symptom outcome

The clinical zinc study tested sulfate.

In 43 people with MS and depression, a 12-week sulfate trial improved depression scores; reported neurological examinations did not differ between groups. [13]

What is still needed. An aspartate trial and adequately tested disease-course outcomes.

Human association · functional potential

A microbial pathway can suggest a mineral question.

The household-paired iMSMS study found increased phytate-degradation pathway potential in untreated MS. This suggests a question about mineral release, not measured zinc transfer. [14]

What is still needed. Pathway activity, zinc speciation and flux, and who acquires any released mineral.

Quantitative cohort · confounding matters

MS-associated taxa do not establish zinc handling.

A quantitative MS study showed that bacterial load and covariates materially affect associations, including the robustness of Akkermansia findings. [15]

What is still needed. A reproducible microbial-function signature that predicts formulation response.

The assembled evidence does not establish that ordinary zinc oxide supplementation worsens MS, or that aspartate helps human MS by denying zinc to microbes. Those are hypotheses with several missing connections, not interchangeable summaries of these studies.

Follow the metal

What would discriminate the explanations?

What the evidence does not establish

The chemical form, organism, compartment, and outcome cannot be swapped across studies. Evidence for a transporter mechanism or an animal response is useful without being a human treatment result. Lower mean serum zinc is likewise not evidence that every person with MS is deficient. [1][12][6]

Open research questions

Questions suggested by the evidence and its limits.

  • Does directly measured microbial zinc acquisition explain formulation responses beyond host absorption alone? [9][11]
  • Do MS-associated functional pathways change zinc transfer in vivo, or are their associations explained by other substrates, treatments, or community features? [14][15]

Follow the connections

Metallomic signatures of diseaseCompare regional brain, spatial tumor, and serum patterns—and the experiments that connect them to microbial function.Calprotectin and metal withholdingThe host protein connecting inflammation with microbial metal competition.Nutritional immunityHow the host changes microbial access to essential nutrients.The metal–microbiome–disease axisThe organizing argument: who gets the metal, in which compartment, and why it matters.Heavy metals and the gut microbiomeAn entry point to exposure, essential nutrients, microbial functions, and disease.Host metal defensesBinding, redistribution, buffering, and biliary export: follow the host strategies and their competing effects.

Selected research

Sources supporting the numbered statements and study summaries above. Publication status is identified where a source reports trial results outside a peer-reviewed paper. This is a curated entry point, not a systematic review.

  1. McDevitt CA et al. (2011). A molecular mechanism for bacterial susceptibility to zinc. View source↩↩↩↩↩↩↩
  2. Liu JZ, Jellbauer S, Poe AJ, Ton V, Pesciaroli M, Kehl-Fie TE, Restrepo NA, Hosking MP, Edwards RA, Battistoni A, Pasquali P, Lane TE, Chazin WJ, Vogl T, Roth J, Skaar EP, Raffatellu M (2012). Zinc sequestration by the neutrophil protein calprotectin enhances Salmonella growth in the inflamed gut. View source↩↩↩↩
  3. Zackular JP, Moore JL, Jordan AT, Juttukonda LJ, Noto MJ, Nicholson MR, Crews JD, Semler MW, Zhang Y, Ware LB, Washington MK, Chazin WJ, Caprioli RM, Skaar EP (2016). Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection. View source↩↩
  4. Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, Crabtree-Hartman E, Sand IK, Gacias M, Zhu Y, Casaccia P, Cree BAC, Knight R, Mazmanian SK, Baranzini SE (2017). Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. View source↩
  5. Henderson LM, Brewer GJ, Dressman JB, Swidan SZ, DuRoss DJ, Adair CH, Barnett JL, Berardi RR (1995). Effect of intragastric pH on the absorption of oral zinc acetate and zinc oxide in young healthy volunteers. View source↩
  6. Pawlitzki M, Uebelhör J, Sweeney-Reed CM, Stephanik H, Hoffmann J, Lux A, Reinhold D (2018). Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls. View source↩↩
  7. Popescu BF, Frischer JM, Webb SM, Tham M, Adiele RC, Robinson CA, Fitz-Gibbon PD, Weigand SD, Metz I, Nehzati S, George GN, Pickering IJ, Brück W, Hametner S, Lassmann H, Parisi JE, Yong G, Lucchinetti CF (2017). Pathogenic implications of distinct patterns of iron and zinc in chronic MS lesions. View source↩
  8. Drmić D, Wang L, Noyer L, Zhong L, Feske S (2026). ZIP3 is essential for the encephalitogenic function of pTh17 cells by regulating intracellular zinc levels. View source↩
  9. Piacenza F, Giacconi R, Costarelli L, Malavolta M (2023). Preliminary Comparison of Fractional Absorption of Zinc Sulphate, Zinc Gluconate, and Zinc Aspartate after Oral Supplementation in Healthy Human Volunteers. View source↩↩↩
  10. Wegmüller R, Tay F, Zeder C, Brnic M, Hurrell RF (2014). Zinc absorption by young adults from supplemental zinc citrate is comparable with that from zinc gluconate and higher than from zinc oxide. View source↩
  11. Maares M, Keil C, Pallasdies L, Schmacht M, Senz M, Nissen J, Kieserling H, Drusch S, Haase H (2022). Zinc availability from zinc-enriched yeast studied with an in vitro digestion/Caco-2 cell culture model. View source↩↩
  12. Schubert C, Guttek K, Grüngreiff K, Thielitz A, Bühling F, Reinhold A, Brocke S, Reinhold D (2014). Oral zinc aspartate treats experimental autoimmune encephalomyelitis. View source↩↩↩
  13. Salari S, Khomand P, Arasteh M, Yousefzamani B, Hassanzadeh K (2015). Zinc sulphate: A reasonable choice for depression management in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. View source↩
  14. iMSMS Consortium (2022). Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. View source↩↩
  15. Pauwels A, Devolder L, Falony G, D'haeseleer M, Nagels G, Van Remoortel A, Derrien M, D'hooghe M, Raes J (2026). Deconfounded, quantitative microbiome profiling identifies robust multiple sclerosis markers and clinical covariate associations. View source↩↩

Continue exploring

23VVanadium25MnManganese26FeIron27CoCobalt28NiNickel29CuCopper

Read the organizing thesis · Follow the metal · How to read different kinds of evidence · Suggest a source or correction